News
08-04-2011, 04:59 AM
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.
More... (http://www.news-medical.net/news/20110804/NanoString-to-begin-clinical-development-program-for-Breast-Cancer-Intrinsic-Subtyping-Assay.aspx)
More... (http://www.news-medical.net/news/20110804/NanoString-to-begin-clinical-development-program-for-Breast-Cancer-Intrinsic-Subtyping-Assay.aspx)